Outcomes of   TP53  ‐mutated  AML  with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival | Zendy

Badar Talha | Zendy; Atallah Ehab | Zendy; Shallis Rory M. | Zendy; Goldberg Aaron D. | Zendy; Patel Anand | Zendy; Abaza Yasmin | Zendy; Bewersdorf Jan P. | Zendy; Saliba Antoine N. | Zendy; Correia Guilherme Sacchi De Camargo | Zendy; Murthy Guru | Zendy; Duvall Adam | Zendy; Burkart Madelyn | Zendy; Stahl Maximilian | Zendy; Liu Yuanhang | Zendy; Dinner Shira | Zendy; Palmisiano Neil | Zendy; Litzow Mark R. | Zendy; Foran James M. | Zendy

Premium

Outcomes of TP53 ‐mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival

Author(s) -

Badar Talha,

Atallah Ehab,

Shallis Rory M.,

Goldberg Aaron D.,

Patel Anand,

Abaza Yasmin,

Bewersdorf Jan P.,

Saliba Antoine N.,

Correia Guilherme Sacchi De Camargo,

Murthy Guru,

Duvall Adam,

Burkart Madelyn,

Stahl Maximilian,

Liu Yuanhang,

Dinner Shira,

Palmisiano Neil,

Litzow Mark R.,

Foran James M.

Publication year - 2022

Publication title -

american journal of hematology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.456

H-Index - 105

eISSN - 1096-8652

pISSN - 0361-8609

DOI - 10.1002/ajh.26546

Subject(s) - medicine , cytarabine , oncology , venetoclax , azacitidine , myeloid leukemia , daunorubicin , transplantation , chemotherapy , induction chemotherapy , clinical trial , leukemia , biochemistry , gene expression , chemistry , chronic lymphocytic leukemia , dna methylation , gene

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research